A rare case of paroxysmal nocturnal hemoglobinuria (PNH) coexisting with diffuse large B-cell lymphoma (DLBCL), a type of blood cancer, was chronicled in a new report that sought to elucidate some of the challenges that can come with the management of the acquired blood disorder co-occurring with this cancer.
Treatment with PiaSky (crovalimab-akkz) controls hemolysis — the destruction of red blood cells in the body — in nearly all people with paroxysmal nocturnal hemoglobinuria (PNH), according to the results of a pooled analysis of published clinical trials. Further, the data also showed that about two-thirds of individuals…
Empaveli (pegcetacoplan) was safely administered during a woman’s pregnancy to manage hard-to-control paroxysmal nocturnal hemoglobinuria (PNH), according to a recent study. Results showed that Empaveli effectively controlled the mother’s PNH, and the baby was born without complications. There were no detectable signs of the medication in…
Doctors for the first time used PiaSky (crovalimab-akkz) to control paroxysmal nocturnal hemoglobinuria (PNH) in a woman with the autoimmune disease systemic lupus erythematosus (SLE), according to a case study. The study’s authors said the case is the seventh documented instance of PNH occurring in someone with…
A case report highlights the steps necessary to prevent dangerous clots and minimize bleeding when performing a cesarean section on someone who has co-occurring paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia, a condition in which the bone marrow fails to produce enough blood cells. Researchers in Greece described the…
Levels of certain immune proteins in the blood may help predict how well people with paroxysmal nocturnal hemoglobinuria (PNH) respond to the therapies Soliris (eculizumab) and PiaSky (crovalimab-akkz), a new study reports. “These findings indicate that higher baseline levels of these markers may help identify patients at…
Vemircopan, a therapy that Alexion, AstraZeneca Rare Disease was developing for paroxysmal nocturnal hemoglobinuria (PNH), increased hemoglobin levels in a Phase 2 study, but frequent episodes of hemolysis — the destruction of red blood cells — were noted. In a…
Despite therapy with complement inhibitors, half of individuals with paroxysmal nocturnal hemoglobinuria (PNH) develop breakthrough hemolysis, or BTH — when PNH symptoms suddenly return despite ongoing treatment — according to a real-world study. The incidence and severity of BTH were found to be particularly high in patients treated with…
Novo Nordisk has entered a license agreement with Omeros for the development and commercialization of zaltenibart (OMS906), an experimental treatment for paroxysmal nocturnal hemoglobinuria (PNH). The deal, expected to be close by year-end 2025, will give Novo Nordisk exclusive global rights for zaltenibart in all indications. Once finalized,…
People switching between treatments for paroxysmal nocturnal hemoglobinuria (PNH) may develop transient immune complex reactions (TICRs) — a type of inflammatory reaction — but these are usually not serious and manageable, a new analysis of more than 200 people finds. The analysis covered people who switched from Soliris…
Get regular updates delivered to your inbox.
